Sanofi (SNY) Rating Lowered to Underweight at Morgan Stanley

Sanofi (NYSE:SNY) was downgraded by Morgan Stanley from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Friday.

Several other equities research analysts have also recently issued reports on SNY. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. raised Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $53.50.

Shares of Sanofi (SNY) opened at $44.62 on Friday. Sanofi has a fifty-two week low of $38.45 and a fifty-two week high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The company has a market capitalization of $112,509.69, a P/E ratio of 14.08, a P/E/G ratio of 2.46 and a beta of 0.86.

Hedge funds have recently bought and sold shares of the business. Bank of Nova Scotia Trust Co. purchased a new position in shares of Sanofi during the third quarter worth $125,000. Parallel Advisors LLC boosted its position in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after buying an additional 875 shares during the period. YorkBridge Wealth Partners LLC boosted its position in shares of Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after buying an additional 776 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in shares of Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after buying an additional 2,098 shares during the period. Finally, Toronto Dominion Bank boosted its position in shares of Sanofi by 4.6% during the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after buying an additional 180 shares during the period. 9.13% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.com-unik.info/2017/12/03/sanofi-sny-rating-lowered-to-underweight-at-morgan-stanley.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit